Compare WOR & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOR | HRMY |
|---|---|---|
| Founded | 1955 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.4B |
| IPO Year | 1998 | 2020 |
| Metric | WOR | HRMY |
|---|---|---|
| Price | $60.84 | $40.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $59.50 | $44.11 |
| AVG Volume (30 Days) | 409.3K | ★ 861.2K |
| Earning Date | 03-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | ★ 63.54 | 7.97 |
| EPS | ★ 3.14 | 1.84 |
| Revenue | ★ $1,381,292,000.00 | $868,453,000.00 |
| Revenue This Year | $22.21 | $19.75 |
| Revenue Next Year | $6.03 | $12.88 |
| P/E Ratio | ★ $19.39 | $21.74 |
| Revenue Growth | 19.72 | ★ 21.51 |
| 52 Week Low | $45.01 | $25.52 |
| 52 Week High | $67.54 | $43.49 |
| Indicator | WOR | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 56.18 | 45.95 |
| Support Level | $52.34 | $37.30 |
| Resistance Level | $63.13 | $43.38 |
| Average True Range (ATR) | 2.67 | 1.16 |
| MACD | 0.28 | -0.37 |
| Stochastic Oscillator | 49.35 | 14.46 |
Worthington Enterprises Inc is a designer and manufacturer of products and services, including manufactured metal products. The company operates under two reportable operating segments: Consumer Products and Building Products. The consumer Products business has a diverse product offering in the tools, outdoor living and celebrations categories, including propane-filled cylinders for torches, handheld torches, specialized hand tools, drywall tools, accessories and gas grills, and others. And the Building Products business engaged in providing pressurized containment solutions, providing critical components in the residential, non-residential, and repair and remodel end markets through essential categories. The company derives majority of the revenue from Building Products segment.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.